Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for the treatment of T-cell lymphomas (TCL), including cutaneous TCL (CTCL).
The designation from the Office of Orphan Products Development at the US Food and Drug Administration (FDA), follows ODD for peripheral TCL (PTCL) in 2022, when Prescient applied for ODD for CTCL.
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF)'s chief executive, Ajan Reginald, hailed the potential of the company’s latest drug development programme.
Its fifth family of drug candidates is focused on a technology called messenger RNA (mRNA), a cutting-edge anti-cancer approach pioneered by leading biotech companies Moderna and BioNTech.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) has announced the completion of a 1,600-person clinical study at a prominent University in Indonesia to validate the company's AI-powered non-invasive screening technology to prepare for the regulatory approval application to classify Safe Entry as a medical device.
As the company's commercialization efforts are underway in Indonesia, it said having Safe Entry classified as a medical device is an integral step to scaling into the landscape of the Indonesian market. The third-party validation of the company's AI-powered screening technology marks yet another milestone for the efficacy of Safe Entry, it added.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a publication in the preeminent journal Proceedings of the National Academy of Sciences (PNAS) that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab.
In a statement, Dr Howard L Weiner, co-director of the Ann Romney Center for Neurologic Diseases at Brigham Women’s Hospital (BWH) and chairman of Tiziana's Scientific Advisory Board, said: “I am proud to be senior author on this important publication. The identification of a unique mechanism associated with nasal foralumab in humans was consistent across patients with COVID, multiple sclerosis and in healthy volunteers."
Toubani Resources Inc. (TSX-V:TRE, ASX:TRE) has released the first set of results from the ongoing drilling program at its Kobada Gold Project in southern Mali which reveal that it has already extended mineralisation by 1 kilometer (km).
The company explained that the drilling was designed to test potential extensions to mineralisation at the Kobada Main Deposit. Extensive artisanal workings can be found along strike and trend from Kobada Main, yet almost no drilling has been undertaken, it said.
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) managing director Shaun Day has told investors that the company's recent exploration campaign at its Scallywag project has delivered "the most encouraging results to date".
The comment came as Greatland announced the results of its 2022 exploration programme at the 100%-owned Scallywag in the Paterson region of Western Australia, which is located adjacent to the company's flagship Havieron gold-copper project discovered in 2018.
Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF) told investors that it has now finalised its planning for the completion and production testing of the State 36-2 well, which is part of the Paradox project in Utah.
It comes after Zephyr in January reported that the well had intersected a major natural fracture network in the Cane Creek reservoir leading to a significant influx of hydrocarbons into the wellbore.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has been granted a US patent for the use of its small molecule immunomodulator, POLB 001, and related p38 MAP kinase inhibitors to treat hypercytokinaemia.
The condition is a hyperinflammatory response to viral infection, cancer or autoimmune response.
Chariot Ltd (AIM:CHAR, OTC:OIGLF) told investors it has now completed the Front-End Engineering and Design (FEED) on the key components of its flagship Anchois gas development project, offshore Morocco.
Engineering, Procurement and Construction (EPC) commercial proposals have now been requested, it added.
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said it has developed a new platform of potential anti-cancer messenger RNA (mRNA) therapeutics, expanding the company's portfolio to five in-house programmes.
The initiative consists of four pre-clinical putative treatments focusing on the company's MDK, or Midkine, target - a protein that plays a key role in the development and progression of cancer.
European Lithium Ltd (ASX:EUR, OTCQB:EULIF) is striding toward becoming a leading producer of battery-grade lithium hydroxide in Europe supported by a robust definitive feasibility study (DFS) for the Wolfsberg Lithium Project in Austria that outlines an NPV of US$1.5 billion and IRR of 33.3%.
The DFS demonstrates that the project is set to deliver high returns, leveraging low operating costs and benefiting from a lithium market anticipated to be in structural undersupply during most of the life of mine.
Western Magnesium Corp. (TSX-V:WMG, OTCQB:MLYF) has announced that all resolutions proposed were passed at its annual general meeting (AGM) held on Tuesday, March 7, 2023. Shareholders voted in favour of all matters brought before them at the meeting, including the re-election of Edward Lee, Sam Ataya, Steve Thorlakson, Jeff Wilson, and Rabih Ataya to the Board of Directors; the appointment of Adeptus Partners LLC as the company’s auditors; and the stock option plan. The percentage of shares represented at the meeting was 43.73% with a total of 121 shareholders, holding 199,655,955 shares. Due to a technical problem with the Microsoft Teams software, unfortunately, a number of shareholders were not able to access the online meeting. We are working with Microsoft to resolve this issue and once this is resolved we will send an invitation for a follow up discussion.
Vivos Therapeutics (NASDAQ:VVOS) has announced that Kirk Huntsman, its chairman and CEO, and Brad Amman, its CFO, will participate in a fireside chat at the 35th Annual ROTH Conference on Tuesday, March 14, 2023 at 1.30pm PT (4.30pm ET). The conference is being held virtually and in-person in Dana Point, CA from March 12-14, 2023. Huntsman and Amman will participate in the fireside chat with ROTH senior research analyst Scott Henry and conduct one-to-one meetings with investors during the conference. Interested parties can access the live webcast of the fireside chat at a link that will be available on Vivos’ investor relations page at: https://vivos.com/investor-relations.
Genprex, Inc. (NASDAQ:GNPX) has announced its participation in the 35th Annual Roth Conference bring held March 12-14, 2023, at the The Ritz-Carlton, Laguna Niguel, Dana Point, California. In attendance at the Roth Conference will be Genprex's chief financial officer, Ryan Confer, and those interested in meeting him during the conference, can request a meeting through the conference portal or reach out to investor relations at investors@genprex.com. Genprex said it will also participate at BIO-Europe Spring being held March 20 - 22, 2023, at Messe Basel, Basel, Switzerland. In attendance at BIO-Europe Spring will be several members of Genprex's executive leadership team and, again, a meeting can be requested through the conference portal or reach out to investor relations at investors@genprex.com. "We are pleased to have members of our Senior Leadership Team participate in these upcoming conferences as they offer an excellent opportunity to highlight the significant potential for our novel gene therapies to address unmet medical needs in oncology and diabetes," said Rodney Varner, chief executive officer of Genprex. "We look forward to providing an overview and update on our clinical development programs, including our Phase 1 dose escalation portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA (quaratusugene ozeplasmid) in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer and our recent groundbreaking data from a non-human primate study evaluating our innovative gene therapy to treat Type 1 diabetes presented at a global medical meeting."
Harbor Custom Development Inc. (NASDAQ:HCDI) told investors that based on its preliminary results, it does not expect to meet its guidance targets for 2022 of full year revenue and adjusted EBITDA of $61 to $65 million and $(7) million to $(5) million loss, respectively. The primary drivers of the miss were a cancellation of a sale of real estate in Punta Gorda, Florida, which was previously under contract and expected to close in the fourth quarter of 2022; cost overruns associated with two fee build projects that are now in final stages of completion; and an impairment charge that was recorded to one of the company's multi-family properties. Harbor plans to provide full year financial results by March 31, 2023.
Versus Systems Inc. (NASDAQ:VS, CSE:VS) is scheduled to participate in the 35th Annual ROTH Conference, which is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, CA from March 12-14, 2023.mVersus management will be available for one-on-one meetings throughout the day on Tuesday, March 14, 2023. To receive additional information, request an invitation or schedule a one-on-one meeting with management, please contact a ROTH representative or the company’s investor relations team at VS@gatewayir.com.
Century Global Commodities Corp (TSX:CNT) announced that it has received notification that a Receiver is in the process of being appointed with respect to the 24,691,628 of its common shares that are registered in the name of Purple Star Holdings Limited. The company said it understands that the Receiver will be appointed pursuant to a loan for which the shares were pledged as security. It also said it understands that a Form 45-102F1 – Notice of Intention to Distribute Securities under Section 2.8 of NI 45-102 has been filed in respect of these shares. The Receiver is expected to file an early warning report and issue a press release upon its appointment in accordance with securities laws, Century added.
Gold Resource Corporation (NYSE-A:GORO, ETR:GIH) revealed that it has published its inaugural environmental, social and governance (ESG) report and has taken “measurable strides” to ensure “proper care and respect” is extended to its employees, communities, and environment. The Denver-based gold and silver producer noted that the ESG report articulates its efforts in the area and shares the framework it has in place to holds itself “accountable.” The report also outlines its approach to sustainability across key governance, health and safety, social and environmental topics, along with a summary of its 2022 performance and plans. “We are committed to advancing our framework as we mature and refine our approach,” said Gold Resource, while saying that the company’s Don David Gold Mine in Mexico has been making investments in ESG endeavors for over 10 years. “Our Back Forty Project in the Upper Peninsula of Michigan has also invested heavily in ESG, including ensuring our environmental impact assessment is robust and thoughtful in identifying culturally significant sites that will be respected,” it added. The ESG report can be found on the company’s website at: www.goldresourcecorp.com/responsible-mining/esg-reports/.